Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.

Abstract: The present invention relates to a GPX4 protein degradation-inducing compound. Specifically, the present invention provides a bifunctional compound in which a GPX4 protein-binding moiety and a CRBN E3 ubiquitin ligase-binding moiety are linked by a chemical linker, a method for preparing the same, a method for degrading a GPX4 protein using the same, and the use for preventing or treating GPX4-related diseases or ferroptosis-related diseases.

Abstract: A floating offshore structure of the present invention comprises: a plurality of columns; and a tower support column for supporting a tower of a power generation structure, wherein a polygonal shape is formed by means of an imaginary line connecting the columns, and the tower supporting column can be provided at one point of one of the sides of the polygonal shape.

Abstract: A floating offshore structure of the present disclosure includes: a plurality of columns; and a plurality of pontoons installed at lower ends of the columns, respectively, wherein a polygonal shape is formed by an imaginary line connecting the columns, the pontoons are installed inside the polygonal shape, a cross-sectional area in a direction parallel to sea level of the pontoons is greater than or equal to the cross-sectional area in the direction parallel to the sea level of the columns, and the pontoons may have a shape protruding outward at the lower ends of the columns.

Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.

Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.

Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.

Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.

Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.

Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.

Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.

Abstract: Disclosed is a method for setting authority for use of a brain stimulation device and a device implementing the same, and the method for setting authority for use of a brain stimulation device according to the present disclosure comprises the steps in which: a communication unit of a personal communication device receives, from a server device, a time token for which the authority for use of the brain stimulation device is set; the communication unit transmits the time token to the brain stimulation device or the server device; and after a time corresponding to the usage time of the brain stimulation device stored in the time token has elapsed, the communication unit receives, from the brain stimulation device or the server device, a message to delete the time token or to change the value of a specific field of the time token.

Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.

Abstract: The present invention relates HMG-CoA reductase degradation inducing compounds. Specifically, the present invention relates a bifunctional compound in which a HMG-CoA reductase binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention also relates a method for preparing the compounds, and a method for degradation of HMG-CoA reductase using the compounds, as well as use for prevention or treatment of HMG-CoA reductase related diseases using the compounds.

Abstract: A device for detecting whether a plurality of electronic components having one or more defective electronic components includes: an energy source generating energy and transferring the generated energy to the plurality of electronic components in a non-contact manner to cause the plurality of electronic components to vibrate; a mechanical resonance detector detecting vibration resonances of the plurality of electronic components; and a post-processing processor comparing the detected vibration resonances of the plurality of electronic components with a reference vibration resonance of a normal product to determine whether the plurality of electronic components have one or more defective electronic components and then extracting determined information.

Abstract: The present invention relates to a cell-penetrating peptide dimer comprising: a first peptide domain consisting of the amino acid sequence of SEQ ID NO: 1; a second 30Kc19? peptide domain consisting of the amino acid sequence of SEQ ID NO: 1; and a peptide linker connecting the first and second peptide domains, a method for preparing the peptide dimer, a cargo delivery system in which a cargo is conjugated to the dimer; and a use thereof. The cell-penetrating peptide dimer according to the present invention may have excellent cell-penetrating properties, thereby being usefully employed as the cargo delivery system.

Abstract: The present invention relates to a novel cell-penetrating recombinant fusion protein including a peptide domain consisting of the amino acid sequence of SEQ ID NO: 1 and a peptide domain consisting of the amino acid sequence of SEQ ID NO: 2. The novel cell-penetrating cereblon recombinant fusion protein according to the present invention may be usefully employed in the prevention or treatment of cereblon-related diseases.

Abstract: The present disclosure relates to a polyethylene fiber and a method for preparing thereof, and more particularly to a polyethylene fiber, a method for preparing thereof, and an apparatus for preparing thereof, which has excellent wearing and touch sensation with processing convenience into woven fabrics and knitted fabrics in use in applied products by reducing the stiffness of fiber having the same physical properties using an enforced necking method in a spinning process.

Abstract: An electronic device is provided. The electronic device includes a housing that forms a rear surface of the electronic device and at least a portion of a side surface of the electronic device, a display that forms a portion of a front surface of the electronic device, a flexible layer extended from the display, the flexible layer including: a bent portion, and a planar portion extended from the bent portion and disposed between the display and the rear surface of the housing, the planar portion including a first surface facing the display and a second surface facing the rear surface, a display driver integrated circuit (DDIC) mounted on the first surface of the planar portion of the flexible layer, the DDIC electrically connected to the display, and a flexible printed circuit board connected with the flexible layer on the second surface of the planar portion of the flexible layer.

Abstract: The present invention relates to a novel cell-penetrating recombinant fusion protein including a peptide domain consisting of the amino acid sequence of SEQ ID NO: 1 and a peptide domain consisting of the amino acid sequence of SEQ ID NO: 2. The novel cell-penetrating cereblon recombinant fusion protein according to the present invention may be usefully employed in the prevention or treatment of cereblon-related diseases.